Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Darunavir/cobicistat"'
Autor:
Alberton F, Galli L, Lolatto R, Candela C, Gianotti N, Chiurlo M, Ranzenigo M, Strano M, Uglietti A, Castagna A
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 1153-1163 (2024)
Francesca Alberton,1 Laura Galli,2 Riccardo Lolatto,2 Caterina Candela,1 Nicola Gianotti,2 Matteo Chiurlo,2 Martina Ranzenigo,2 Martina Strano,2 Alessia Uglietti,3 Antonella Castagna1,2 1Infectious Diseases Unit, Vita Salute San Raffaele University,
Externí odkaz:
https://doaj.org/article/3a3b0b24e5e04fc4b0199f8dcd0a6316
Autor:
Ruxandra-Cristina Marin, Simona Gabriela Bungau, Delia Mirela Tit, Paul Andrei Negru, Andrei-Flavius Radu, Radu Dumitru Moleriu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 161, Iss , Pp 114427- (2023)
Approximately two-thirds of Romanian HIV patients were parenterally infected with the F subtype of HIV in early childhood. They are now in the context of immunological aging, with immunosuppression posing an additional challenge in developing the mos
Externí odkaz:
https://doaj.org/article/258468eca89340ee9971eec42eda97ee
Autor:
Lucia Taramasso, Elena Ricci, Antonio Cascio, Laura Valsecchi, Barbara Menzaghi, Nicola Squillace, Paolo Maggi, Giuseppe Vittorio De Socio, Chiara Dentone, Giordano Madeddu, Giovanni F. Pellicanò, Leonardo Calza, Goffredo Angioni, Paolo Bonfanti, Antonio Di Biagio, CISAI Study Group
Publikováno v:
AIDS Research and Therapy, Vol 16, Iss 1, Pp 1-8 (2019)
Abstract Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity An
Externí odkaz:
https://doaj.org/article/90c88e2279ca44fc8c2833e4b9a33709
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 12, Pp 3635-3643 (2018)
Nicola Squillace,1 Giorgio Bozzi,2 Elisa Colella,1 Andrea Gori,2 Alessandra Bandera1 1Infectious Diseases Unit, Azienda Socio Sanitaria Territoriale di Monza, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 2Infectious Disease Unit,
Externí odkaz:
https://doaj.org/article/ac45cd69c06a46d6afc74a49994cbfaa
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hélène Hardy, Wing Chow, Aurélie Côté-Sergent, Patrick Lefebvre, Prina Donga, Bruno Emond, Marie-Hélène Lafeuille, Carmine Rossi
Publikováno v:
Patient preference and adherence
Wing Chow,1 Prina Donga,1 Aurélie Côté-Sergent,2 Carmine Rossi,2 Patrick Lefebvre,2 Marie-Hélène Lafeuille,2 Hélène Hardy,2 Bruno Emond3 1Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Analysis Group, Inc.,
Autor:
Yong Shik Kwon, Eun Jin Kim, Jae Seok Park, Shin Yup Lee, Sun Ha Choi, Eun Young Choi, Jaehee Lee, Yeonjae Kim
Publikováno v:
Yonsei Medical Journal
We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receiv
Autor:
Alessandra Vergori, Elio Manzillo, Roberta Termini, Andrea Antinori, Diego Ripamonti, Antonella dʼArminio Monforte, Christof Stingone, Nicola Gianotti, Stefano Savinelli, Benedetto Maurizio Celesia, Francesco Castelli, Renato Maserati, Teresa Santantonio, Giancarlo Orofino, Barbara Menzaghi, Francesco Rucci, Maria Vittoria Cossu, Roberto Cauda, Gaetana Sterrantino, Anna Maria Cattelan, Alessia Uglietti, Andrea Gori, Stefano Rusconi, Daniela Mancusi, Stefano Bonora
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Objective: This study investigates the effectiveness and tolerability of switching to a darunavir/cobicistat (DRV/c)-based antiretroviral regimen from a ritonavir-boosted protease inhibitor (PI/r)-based regimen in virologically suppressed HIV-positiv
Autor:
Podzamczer, D., Micán, R., Tiraboschi, J., Portilla, J., Domingo, P., Llibre, J. M., Macías Sánchez, Juan, Moreno, S.
Background. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3272::bfc59ded9a1c33a7ca457775874256b6